Ivabradine to Prevent Anthracycline-induced Cardiotoxicity

  • days left to enroll
  • participants needed
  • sponsor
    University of Sao Paulo
Updated on 23 January 2021


Anthracyclines are associated with cardiotoxic effects. Previous studies suggest that enalapril, and or carvedilol, protect against cardiovascular effects of these drugs.

Ivabradine selectively reduces heart rate through inhibition of the cardiac pace maker IF channel, thus prolonging the duration of spontaneous depolarization in the sinus node. Additionally, ivabradine might preserve myocardial perfusion without negative inotropic effect and probably maintain cardiac contractility despite the reduction of heart rate.

Ivabradine has been shown to improve outcome in patients with heart failure and angina. The aim of this study is to evaluate whether ivabradine might prevent anthracycline-induced cardiotoxicity.

Condition Cancer, Heart failure, Heart disease, Diet and Nutrition, Chronic Diarrhea, Skin Wounds, Chronic Shoulder Pain, Vaginal Atrophy, Adverse Effects, Drugs, Injection Port, Breast Cancer - HER2 Positive, Anal Dysplasia, Primary Immunodeficiency, Pediatric Health, Near-Sighted Corrective Surgery, Cancer/Tumors, Cardiotoxicity, Peripheral Arterial Occlusive Disease, Ewing's Family Tumors, Brain Function, Chemotherapy Effect, Cardiac Toxicity, Oncology, Recurrent Respiratory Papillomatosis, Razor Bumps (Pseudofolliculitis Barbae), Cancer (Pediatric), Metastatic Triple-Negative Breast Cancer, Congestive Heart Failure, Neoplasms, Cardiac Disease, cardiac failure, congestive heart disease
Treatment Placebo, Ivabradine
Clinical Study IdentifierNCT03650205
SponsorUniversity of Sao Paulo
Last Modified on23 January 2021


Yes No Not Sure

Inclusion Criteria

Age 18-year-old or older
Cancer diagnosis
Chemotherapy with anthracycline
Written informed consent

Exclusion Criteria

Chronic Kidney Disease (Creatinine clearance inferior to 30mL/min/1.73m2)
Bradycardia (heart rate less than 60 beats per minute)
Atrial fibrilation
Previous diagnosis of heart failure
History of previous hypersensibility to the study drug
Participating in another study protocol
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note